ePrivacy and GPDR Cookie Consent by Cookie Consent
Our biomarker tests 


Pan-cancer biomarker test on liquid biopsy

Sample type:

Liquid biopsy

2 blood samples

Scroll down to discover

Targeted Liquid Biopsy to Support Your Clinical Decisions


OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample for all advanced cancer patients.

When patients cannot have their tumor biopsied, when their tumor tissue sample is too old or too scarce for comprehensive biomarker testing, OncoSELECT is the perfect alternative to help in treatment strategies optimization and to support clinical decisions. It can be used as a tool to detect treatment resistance to targeted therapies and hormone therapies (before first line to assess the heterogeneity of the disease, or during/after treatment to check for acquired resistance mutations or to inform on the patient's response to chemotherapy in neoadjuvant settings) as well as determine patient potential eligibility to clinical trials.

Sample Type:

Liquid biopsy

Recommended for:

  • All types of stage III and IV solid tumors in adults

Genes panel:

  • - 58 genes 
  • - SNVs, Indels 
  • - Gene translocations, unusual splicing
  • - TERT promoter

Gene list


2 blood samples (2x10ml Streck tubes)

The Added Value of ctDNA

Patient Case Studies

Other Biomarker Tests

COMPREHENSIVE BIOMARKER TEST to support clinical decisions

OncoDEEP® offers a unique combination of DNA, RNA and protein biomarker tests on solid biopsies. In less than two weeks, OncoDEEP is able to pinpoint the therapeutic vulnerabilities of an advanced, metastatic tumor and to recommend appropriate treatment options. The test screens for genomic alterations (DNA & RNA), genomic signatures (MSI, TMB, HRD) and protein biomarkers of response to targeted therapies, immunotherapies, hormone therapy and chemotherapy.

Personalised liquid biopsy for patient monitoring

OncoFOLLOW is a test based on the analysis of circulating tumor DNA in blood. It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears.

This assay is customised for each patient, as it analyses variants previously identified in the tumour of the patient.

In 2013, OncoDNA became the first company to launch a personalised liquid biopsy test.


Ordering a solution is very simple: Just log in to OncoSHARE and select the solution(s) you are interested in. If you do not have a kit for sample collection, we will send you one.

After sample processing and interpretation by our expert team, a comprehensive report will be available for you on OncoSHARE. In a simple and interactive manner, it will help you with the selection of the most appropriate treatments based on the unique signature of your patient's tumour. Moreover, you will be able to share the report with your colleagues.

For information regarding the price of our OncoSELECT biomarker test in your respective country, please contact our sales team.

Cannot find what you are looking for? Contact us! Our Scientific Support Teams are available to answer all your questions from Monday to Friday.

Relevant news